Masimo

Masimo Corp. is a medical technology company, which develops, manufactures and markets noninvasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Masimo reports robust Q4 earnings, eyes new product launches

Masimo's Q4 2022 earnings call highlighted strong financial performance, growth projections for 2023, and a focus on innovation and regulatory advancements. While facing challenges like supply chain issues and legal disputes, the company remains optimistic about opportunities in new product launches and revenue growth drivers. Overall, Masimo is poised for continued success in the healthcare market.

Masimo reports robust Q1 earnings, navigates challenges with strategic focus

Masimo's Q1 performance reflects strong revenue growth and product innovation, underpinned by a focus on healthcare technology and wearables for chronic illness monitoring.
While facing challenges such as litigation costs and regulatory clearances, Masimo maintains its financial guidance for 2023, signaling stability and strategic resilience.
The company's emphasis on new product launches, diverse pricing strategies, and global market expansion positions it well to capitalize on opportunities in the healthcare sector.

Masimo faces revenue challenges in Q2 but eyes rebound

Masimo's Q2 performance was impacted by revenue challenges in Healthcare and non-healthcare segments, leading to a revised revenue guidance for 2023.
The company is focusing on expense control measures, new product opportunities, and pricing discipline to drive profitability and rebound in business segments.
Despite challenges, Masimo remains optimistic about market opportunities in telehealth, consumer health, and the potential for revenue growth from products like Stork.
Ongoing litigation with Apple and uncertainties in customer order patterns pose challenges, but the company is implementing strategies to address these issues.

Masimo reports solid Q3 earnings, eyes growth in consumer health

Masimo's Q3 performance showcased strong revenue but challenges in sensor utilization recovery. The company's innovative products and expansion into consumer health signal growth potential. Addressing challenges in revenue guidance and market competition will be key focus areas for future success.

Masimo reports robust Q4 earnings, legal wins and growth opportunities

Masimo's strong Q4 performance and strategic focus on healthcare and hearables/wearables growth position the company well for 2024.
Legal victories in Apple litigation and FDA clearances for innovative products underscore Masimo's commitment to innovation and protecting its intellectual property.
While facing challenges in legal proceedings and product clearances, Masimo has opportunities to drive revenue growth through product innovation and market expansion.

Masimo reports strong Q1 earnings, plans consumer business separation

Masimo's Q1 2024 Earnings Call showcased robust financial performance, strategic revenue diversification, and plans for enhancing shareholder value through potential separation of the consumer business. While facing challenges in operational transitions and financial metrics scrutiny, the company is well-positioned for growth and value creation.

Masimo reports robust Q3 performance and outlines growth opportunities

Masimo's Q3 2024 earnings call showcased strong financial performance, strategic reviews, and growth initiatives. While facing challenges in margin progression and potential disruptions, the company is poised for growth with opportunities in revenue expansion and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Masimo Corp. is a global technology company, which engages in the development, manufacture, and marketing of patient monitoring technologies, and automation and connectivity solutions. Its products include remote patient monitoring, connectivity, and hospital automation solutions, including Masimo Patient SafetyNet, Masimo Patient SafetyNet Surveillance, Masimo SafetyNet, Masimo SafetyNet-Open, Replica, Iris, MyView, UniView, Uniview: 60, Trace, Masimo Sleep, Centroid, and Bridge. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Masimo's (MASI) new solution can help reduce symptoms associated with opioid withdrawal, thereby helping OUD patients with their treatment.

Masimo's New Solution to Reduce Opioid Withdrawal Symptoms

Masimo's (MASI) Centroid gets FDA clearance and can help clinicians monitor patient position, thereby improving patient outcomes.

Masimo's (MASI) New Offering to Improve Patient Outcomes

Allscripts Healthcare Solutions

Medtronic

Let's keep a watch on three stocks that are committed toward enhancing and offering RPM to fight against coronavirus.

Remote Patient Monitoring Gains Prominence: 3 Stocks to Watch

Masimo (MASI) unveils Masimo Sleep to help consumers better understand their quality of sleep.

Masimo (MASI) Boosts Product Portfolio with New Solution

Masimo's (MASI) newly-launched SafetyNet-Open has been developed to ensure health and safety during the coronavirus outbreak.

Masimo Launches Masimo SafetyNet-Open to Fight Coronavirus

This medical device maker and its shares have surged during the pandemic -- but the company may not be positioned well for what comes after.

Can This COVID-19 Hero Stock Maintain Its Momentum?

Veeva Systems

In the face of the pandemic, the digital health management space continues to thrive on a number of positive developments.

3 Digital HealthCare Stocks in the Spotlight Amid Coronavirus

iRhythm Technologies

SPDR S&P Kensho New Economies Composite ETF

Bullish chart patterns on the KOMP ETF and its top holdings suggest that it could be an ideal time to increase exposure to innovative tech companies.

3 Ways Traders Are Gaining Exposure to Changes in Tech

West Pharmaceutical Services

Finding Health Care Companies We Believe Can Thrive In A Post-COVID-19 Environment

Align Technology

Intuitive Surgical

Wall Street is looking forward to a return to normalcy in the healthcare sector.

Why These 3 Top Medical Tech Companies Rose More Than 12% in May

Masimo (MASI) closed the most recent trading day at $220.24, moving +0.75% from the previous trading session.

Masimo (MASI) Gains But Lags Market: What You Should Know

Masimo Corporation, a medical devices company best known for its remote patient monitoring systems, has seen its stock grow by about 50% from $158 at the beginning of the year to $237 currently, outperforming the broader indices, due to the increased demand for its products in the wake of the.

After A Massive 60% Rise Since March Lows, Has Masimo Stock Run Its Course?

Masimo (MASI) reported earnings 30 days ago. What's next for the stock?

Why Is Masimo (MASI) Up 5.3% Since Last Earnings Report?

Royal Philips

Masimo and Philips licensing agreement brings Masimo NomoLine® Capnography and O3® Regional Oximetry to select Philips patient monitors

Masimo Corporation , a medical devices company best known for its remote patient monitoring systems, has seen its stock outperform through the coronavirus, rising by almost 56% year-to-date, compared to the broader S&P which is down ~10%.

After A Whopping 200% Move, Is It Time To Sell Masimo?

Investor confidence remains high in Masimo (MASI) stock, thanks to solid prospects.

Here's Why You Should Retain Masimo Stock (MASI) For Now

Masimo CEO Joe Kiani discussed how the medical device maker's telehealth systems can be useful in the fight against coronavirus.

Masimo CEO says its remote oxygen monitors were made to mitigate diseases like coronavirus

Masimo (MASI) sees solid growth in key Product segment in Q1.

Masimo (MASI) Q1 Earnings Beat Estimates, Margins Expand

Masimo Corp (MASI) CEO Joe Kiani on Q1 2020 Results - Earnings Call Transcript

Generac Holdings

HealthEquity

Procter & Gamble

Prologis

ResMed

Shopify

Teladoc

Thor Industries

Five ways the coronavirus pandemic will change our thinking and create stock-buying opportunities.

9 Stocks for a Post-Pandemic World

Masimo (MASI) and Samsung Electronics America collaborate to bring Masimo SafetyNet Patient App on the latter's select smartphones for faster distribution of Masimo SafetyNet to COVID-19 patients.

Masimo Collaborates With Samsung to Help Fight Coronavirus

Amazon

Netflix

Regeneron Pharmaceuticals

Zoom Video

Here we discuss five stocks poised to gain maximum benefits from the staggered reopening of U.S. economy, per the latest guidelines.

Trump Plans Steady Economic Reboot: 5 Coronavirus-Proof Bets

Amedisys

Chewy

DocuSign

Five9

Eli Lilly

Moderna

Walmart

The COVID-19 pandemic staggered economic activity and decreased consumer spending.

10 Stocks Hitting All-Time Highs Amid The COVID-19 Pandemic

Let's keep a watch on three stocks that are focusing on digital health to fight against coronavirus.

Coronavirus Puts Digital Health in Focus: 3 Stocks to Watch

Does Masimo (MASI) have what it takes to be a top stock pick for momentum investors? Let's find out.

News for Masimo Stock (MASI)